Cycle Pharmaceuticals Partners With Forma Life Sciences for CAVHANZA Supply
IRVINE, Calif., August 12, 2026 Cycle Pharmaceuticals announced a commercial manufacturing agreement with Forma Life Sciences to establish a...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
IRVINE, Calif., August 12, 2026 Cycle Pharmaceuticals announced a commercial manufacturing agreement with Forma Life Sciences to establish a...
Bridgewater, N.J., August 10, 2026 Grifols announced the completion of patient follow-up in SPARTA, its Phase 3 outcomes study...
Bridgewater, N.J., August 10, 2026 Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC, creating a scaled,...
PLAINSBORO, New Jersey, USA / BAGSVÆRD, Denmark, July 11, 2026 Novo Nordisk has announced positive long-term Phase 3 results...
SILVER SPRING, Maryland, July 10, 2026 The U.S. Food and Drug Administration (FDA) has proposed a new rule designed...
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
MUMBAI, India, May 28, 2026 Lupin Limited, one of the world’s leading pharmaceutical companies, has announced that it has...
HUNTSVILLE, Ala. and KASSEL, Germany, May 20, 2026 Discovery Life Sciences has launched Luminos® Comprehensive, a next-generation IVDR-compliant clinical...
JERUSALEM, Israel, May 20, 2026 Scinai Immunotherapeutics Ltd. has announced the appointment of Eilon Elmalem as the new Site...
MONTREAL, April 29, 2026 Pharmascience Canada has announced the official launch of ᴾʳpms-DOLUTEGRAVIR (dolutegravir tablets), marking an important milestone...
